CAS: 2290608-13-6
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide REF: 3D-QRD60813CAS: 2290608-13-6 | Min. 95% | To inquire | Tue 21 Jan 25 |
 | VT103 REF: TM-T62077CAS: 2290608-13-6 | 98.73% | 121.00 €~3,690.00 € | Tue 28 Jan 25 |
N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide
CAS:2290608-13-6
Please enquire for more information about N-Methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)phenyl)amino)benzenesulfonamide including the price, delivery time and more detailed …
Formula:
C18H17F3N4O2S
Purity:
Min. 95%
Molecular weight:
410.4 g/mol
Ref: 3D-QRD60813
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025
VT103
CAS:2290608-13-6
VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.
Formula:
C18H17F3N4O2S
Purity:
98.73%
Color and Shape:
Liquid
Molecular weight:
410.41
Ref: TM-T62077
| 1mg | 121.00 € | ||
| 5mg | 291.00 € | ||
| 10mg | 461.00 € | ||
| 25mg | 828.00 € | ||
| 50mg | 1,345.00 € | ||
| 100mg | 1,841.00 € | ||
| 1mL*10mM (DMSO) | 320.00 € |
Estimated delivery in United States, on Tuesday 28 Jan 2025
